Trend in rifampicin-, multidrug- and extensively drug-resistant tuberculosis in Italy, 2009–2016. Issue 1 (19th July 2018)

• Record Type: Journal Article
• Authors: Mustazzolu, Alessandro; Borroni, Emanuele; Cirillo, Daniela Maria; Giannoni, Federico; Iacobino, Angelo; Fattorini, Lanfranco
• Other Names: Ghisetti V. author non-byline.; Mondo A. author non-byline.; Avolio M. author non-byline.; Barbui A. author non-byline.; Lorenzetti P. author non-byline.; De Renzi G. author non-byline.; Chirillo M.G. author non-byline.; Molinari G. author non-byline.; Camaggi A. author non-byline.; Andreoni S. author non-byline.; Piana F. author non-byline.; Marchese A. author non-byline.; Gritti P. author non-byline.; Icardi G. author non-byline.; Varnier O. author non-byline.; Mazzola E. author non-byline.; Gesu G. author non-byline.; Cichero P. author non-byline.; Lombardi A. author non-byline.; Libanori E. author non-byline.; Viggiani P. author non-byline.; De Lorenzo S. author non-byline.; Pinsi G. author non-byline.; Marone P. author non-byline.; Monzillo V. author non-byline.; Barbarini D. author non-byline.; Farina C. author non-byline.; Arosio M. author non-byline.; Peracchi M. author non-byline.; Manganelli R. author non-byline.; Fabris C. author non-byline.; Di Santolo M. author non-byline.; Busetti M. author non-byline.; Scarparo C. author non-byline.; Sartor A. author non-byline.; Pedrotti C. author non-byline.; Caola I. author non-byline.; Frizzera E. author non-byline.; Dal Monte P. author non-byline.; Pietrosemoli P. author non-byline.; Pecorari M. author non-byline.; Fabio A. author non-byline.; la Regina A. author non-byline.; Matteucci M. author non-byline.; Piersimoni C. author non-byline.; Bartolesi A. author non-byline.; Mannino R. author non-byline.; Simonetti T. author non-byline.; Tortoli E. author non-byline.; Rindi L. author non-byline.; Mencacci A. author non-byline.; Cenci E. author non-byline.; Luciano E. author non-byline.; Mazzolla R. author non-byline.; Sanguigni I. author non-byline.; Parisi G. author non-byline.; Chiaradonna P. author non-byline.; Altieri A.M. author non-byline.; D'Arezzo S. author non-byline.; Mazzarelli A. author non-byline.; Di Caro A. author non-byline.; Bordi E. author non-byline.; Sali M. author non-byline.; Delogu G. author non-byline.; Sanguinetti M. author non-byline.; Russo C. author non-byline.; Coltella L. author non-byline.; Ciocco A. author non-byline.; Meledandri M. author non-byline.; Gambi A. author non-byline.; Tomei G. author non-byline.; Conte M. author non-byline.; Santoro G. author non-byline.; del Giudice A. author non-byline.; Nuzzolese N. author non-byline.; Vitullo E. author non-byline.; Sinno A. author non-byline.; Buono L. author non-byline.; Costa D. author non-byline.; Grimaldi A. author non-byline.; Di Taranto A. author non-byline.; De Nittis R. author non-byline.; Palumbo G. author non-byline.; Dodaro S. author non-byline.; Giraldi C. author non-byline.; Cavalcanti P. author non-byline.; Nisticò S. author non-byline.; Vinci L. author non-byline.; Di Naso C. author non-byline.; Bonura C. author non-byline.; Maida C.M. author non-byline.; Mammina C. author non-byline.; Podda G.S. author non-byline.; Caddeu R. author non-byline.;
• Is Part Of: European respiratory journal. Volume 52:Issue 1(2018)
• Publication Date: 2018-07-19
• Subjects: Respiratory organs -- Diseases -- Periodicals; Respiration -- Periodicals; 616.2
• DOI: 10.1183/13993003.00070-2018
• Languages: English
• ISSNs: 0903-1936

Abstract

Tuberculosis (TB) caused by strains of Mycobacterium tuberculosis that are rifampicin-resistant (RR), multidrug-resistant (MDR) (strains resistant to at least isoniazid and rifampicin) or extensively drug-resistant (XDR) (MDR strains resistant to any fluoroquinolone (FQ) and to at least one second-line injectable drug (SLID): kanamycin, capreomycin or amikacin) is a major threat to TB control globally. All three groups require treatment with second-line drugs (SLDs) [1]. We previously reported that MDR- and XDR-TB in Italy occurred mostly in foreign-born persons (FBPs) [2, 3], but no major information on RR, MDR or XDR trends in FBPs and Italian-born persons (IBPs) were shown. Here, we documented these trends from 2009 to 2016 (figure 1). In Italy, rifampicin-resistant and MDR-TB were high in foreign-born persons, but decreased from 2009 to 2016 http://ow.ly/MrIy30jNjFj